Search Results - "Iliopoulos, O."

Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential by Heddleston, J M, Wu, Q, Rivera, M, Minhas, S, Lathia, J D, Sloan, A E, Iliopoulos, O, Hjelmeland, A B, Rich, J N

“…Normal stem cells reside in functional niches critical for self-renewal and maintenance. Neural and hematopoietic stem cell niches, in particular, are…”
Get full text

Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential by Heddleston, J M, Wu, Q, Rivera, M, Minhas, S, Lathia, J D, Sloan, A E, Iliopoulos, O, Hjelmeland, A B, Rich, J N

Get full text

Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase by Kamura, T., Koepp, D. M., Conrad, M. N., Skowyra, D., Moreland, R. J., Iliopoulos, O., Lane, W. S., Kaelin, W. G., Elledge, S. J., Conaway, R. C., Harper, J. W., Conaway, J. W.

“…The von Hippel-Lindau (VHL) tumor suppressor gene is mutated in most human kidney cancers. The VHL protein is part of a complex that includes Elongin B,…”
Get full text

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC) by Meric-Bernstam, F, Tannir, N, Harding, J, Voss, M, Mier, J, DeMichele, A, Munster, P, Patel, M, Iliopoulos, O, Owonikoko, T, Whiting, S, Orford, K, Bennett, M, Carvajal, R, McKay, R, Fan, A, Telli, M, Infante, J

“…Background: CB-839 is a first-in-class highly selective inhibitor of glutaminase (GLS), a key enzyme in the utilization of glutamine by many cancer types…”
Get full text

Negative Regulation of Hypoxia-Inducible Genes by the von Hippel--Lindau Protein by Iliopoulos, Othon, Levy, Andrew P., Jiang, Chian, Kaelin, William G., Goldberg, Mark A.

“…Inactivation of the von Hippel--Lindau protein (pVHL) has been implicated in the pathogenesis of renal carcinomas and central nervous system hemangioblastomas…”
Get full text

Genetic and clinical aspects of familial renal neoplasms by Iliopoulos, O, Eng, C

“…Genetic studies of families at high risk for developing malignant and benign renal neoplasms led to cloning of genes whose alteration results in tumor…”
Get more information

Innovations and challenges in renal cancer: Consensus statement from the First International Conference by ATKINS, Michael B, AVIGAN, David E, GOLDBERG, S. Nahum, GORDON, Michael S, ILIOPOULOS, Othon, KAELIN, William G, LINEHAN, W. Marston, LIPTON, Allan, MOTZER, Robert J, NOVICK, Andrew C, STADLER, Walter M, BIN TEAN TEH, BUKOWSKI, Ronald M, YANG, James C, KING, Laura, CHILDS, Richard W, DUTCHER, Janice P, EISEN, Tim G, FIGLIN, Robert A, FINKE, James H, FLANIGAN, Robert C, GEORGE, Daniel J

Get full text

von Hippel-Lindau disease: genetic and clinical observations by Iliopoulos, O

Get more information

83P Impact of VHL-associated tumor treatment on mental health: An international patient survey by Iliopoulos, O., Atkinson, C., Cooper, C., Taylor-Stokes, G., Mann, J., Sundaram, M.

Get full text

Functions of the von Hippel–Lindau tumour suppressor protein by KAELIN, W. G, ILIOPOULOS, O, LONERGAN, K. M, OHH, M

“…Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M (Dana‐Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA). Functions of the von Hippel–Lindau…”
Get full text

LBA69 Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study by Srinivasan, R., Iliopoulos, O., Rathmell, W.K., Narayan, V., Maughan, B.L., Oudard, S., Else, T., Maranchie, J.K., Welsh, S.J., Iversen, A.B. Bøndergaard, Chen, K., Perini, R.F., Liu, Y., Linehan, W.M., Jonasch, E.

Get full text

The molecular basis of von Hippel-Lindau disease by Iliopoulos, O, Kaelin, Jr, W G

Get full text

Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils by Iliopoulos, O, Baroody, FM, Naclerio, RM, Bochner, BS, Kagey-Sobotka, A, Lichtenstein, LM

“…The pattern of mediators and appearance of cells that stain with alcian blue during human experimental early and late phase allergic reactions suggest that…”
Get full text

LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease by Srinivasan, R., Donskov, F., Iliopoulos, O., Rathmell, W.K., Narayan, V.K., Maughan, B.L., Oudard, S., Else, T., Maranchie, J.K., Welsh, S.J., Thamake, S., Park, E.K., Perini, R.F., Linehan, W.M., Jonasch, E.

Get full text

The risk of Von Hippel-Lindau disease according to individual sporadic cancer in a multidisciplinary program: External validation of the VHL Alliance guidelines for genetic referral by Larcher, A., Fallara, G., Rowe, I., Belladelli, F., Iliopoulos, O., Doglioni, C., Lucianò, R., Casari, G., Carrera, P., Patricelli, M.G., Falini, A., De Cobelli, F., Mortini, P., Capitanio, J., Bailo, M., Bandello, F., Lattanzio, R., Falconi, M., Partelli, S., Muffatti, F., Necchi, A., Montorsi, F., Capitanio, U., Salonia, A.

Get full text

Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells by Chung, Daniel C, Mizukami, Yusuke, Jo, Won-Seok, Duerr, Eva-Maria, Gala, Manish, Li, Jingnan, Zhang, Xiaobo, Zimmer, Michael A, Iliopoulos, Othon, Zukerberg, Lawrence R, Kohgo, Yutaka, Lynch, Maureen P, Rueda, Bo R

“…Hypoxia inducible factor-1 (HIF-1) is considered a crucial mediator of the cellular response to hypoxia through its regulation of genes that control…”
Get full text

Loss of RBF1 changes glutamine catabolism by Nicolay, Brandon N, Gameiro, Paulo A, Tschöp, Katrin, Korenjak, Michael, Heilmann, Andreas M, Asara, John M, Stephanopoulos, Gregory, Iliopoulos, Othon, Dyson, Nicholas J

“…Inactivation of the retinoblastoma tumor suppressor (pRB) alters the expression of a myriad of genes. To understand the altered cellular environment that these…”
Get full text

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors by Zimmer, Michael, Doucette, Darrell, Siddiqui, Naila, Iliopoulos, Othon

“…The von Hippel-Lindau tumor suppressor protein (pVHL) is a substrate receptor for the mammalian SCF-2 E3 ubiquitin ligase complex that targets several…”
Get full text

Abstract PD3-13: Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer by Kalinsky, K, Harding, JJ, DeMichele, A, Infante, JR, Gogineni, K, Owonikoko, TK, Isakoff, S, Iliopoulos, O, Patel, MR, Munster, P, Telli, ML, Jenkins, Y, Fiji, GP, Whiting, SH, Meric-Bernstam, F

“…Abstract Background: CB-839 is a first-in-class oral highly selective inhibitor of glutaminase (GLS), a mitochondrial enzyme that plays a key role in cancer…”
Get full text

26 - Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC) by Meric-Bernstam, F., Tannir, N., Harding, J., Voss, M., Mier, J., DeMichele, A., Munster, P., Patel, M., Iliopoulos, O., Owonikoko, T., Whiting, S., Orford, K., Bennett, M., Carvajal, R., McKay, R., Fan, A., Telli, M., Infante, J.

Get full text